查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2037567

臨床試驗市場預測至2034年－按階段、研究設計、適應症、介入類型、最終使用者和地區分類的全球分析

Clinical Trials Market Forecasts to 2034 - Global Analysis By Phase, Study Design, Indication, Intervention Type, End User, and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，預計到 2026 年，全球臨床試驗市場規模將達到 873 億美元，並在預測期內以 7.9% 的複合年成長率成長，到 2034 年將達到 1,604 億美元。

臨床試驗是指以人體為研究對象，評估藥物、生物製藥、醫療設備和治療方案等醫療介入措施的安全性、有效性和副作用的研究。這些研究構成了實證醫學的基礎，並為獲得美國食品藥物管理局（FDA）和歐洲藥品管理局（EMA）等監管機構的核准提供了關鍵數據。該市場涵蓋了一個複雜的生態系統，包括製藥公司、合約研究組織（CRO）、臨床試驗中心和技術供應商，各方通力合作，共同推動不同疾病領域治療方法的研發。

慢性病和罕見病患疾病率增加

癌症、糖尿病和心血管疾病等慢性疾病的全球負擔持續加重，迫切需要新的治療方法。同時，對遺傳機制的深入了解使得針對數千種先前無藥可醫的罕見疾病開發標靶治療成為可能。醫療保健系統面臨的雙重壓力迫使製藥公司拓展其在多個治療領域的臨床開發平臺。政府對孤兒藥研發的獎勵和快速核准流程進一步刺激了對臨床研究的投資，隨著申辦方競相為治療選擇有限的患者提供創新治療方法，臨床試驗的註冊數量逐年增加。

招募和留住參與者面臨的主要挑戰

臨床試驗的成功取決於是否能在規定時間內招募到合格的受試者，然而，受試者招募困難仍是導致試驗延長和取消的主要原因。識別符合複雜納入和排除標準的合適候選人需要廣泛的臨床實驗中心網路和積極主動的患者聯絡工作。即使受試者入組後，如何確保他們遵守試驗方案要求、按時訪視以及完成通常繁瑣的程序仍然是一個持續的挑戰，這可能會影響數據品質。這些受試者招募和保留問題會延長研發週期、增加成本，甚至導致統計結果不足，需要進行額外的驗證性試驗，從而給臨床實驗試驗中心帶來巨大的經濟壓力，並嚴重影響罕見疾病（患者群體有限）的臨床實驗。

分散式和虛擬臨床試驗的調查方法

數位健康技術的應用正在從根本上改變臨床研究的進行方式，使遠端參與和數據收整合為可能。穿戴式感測器、行動應用程式和遠端醫療平台讓患者能夠在家中提供數據，從而減少了地域限制和出行負擔，而這些限制曾阻礙了傳統的以醫療機構為基礎的入組方式。電子知情同意、直接向患者配送藥物以及居家醫療服務進一步擴大了不同人群的參與範圍，並提高了試驗結果的普適性。這些分散式方法能夠縮短招募週期，降低脫落率，同時收集更豐富的真實世界數據，為申辦者提高研發效率和降低日益成長的臨床研究成本創造了重要機會。

不斷變化的監管環境和合規環境

不斷演變且日益複雜的全球監管要求對可預測的臨床開發進度和預算構成重大威脅。主要市場在數據標準、安全性報告和倫理監管方面的要求差異，給開展跨國試驗的申辦者帶來了沉重的營運負擔。包括GDPR及類似框架在內的新資料隱私法規限制了受試者資訊的收集和跨境傳輸，而這對於現代研究至關重要。此外，對臨床試驗多樣性和代表性的日益嚴格的審查，迫使申辦者重新思考其受試者招募策略並擴大其研究中心網路。應對這種動態的合規環境需要持續投資於專業知識和系統，這反過來又會擠壓合約研究組織（CRO）的利潤空間。

新冠疫情的影響：

新冠疫情為臨床試驗帶來了前所未有的衝擊，但也加速了創新調查方法的應用。 2020年初，由於試驗中心暫停招募病患並將資源轉向疫情應對，數千項非新冠相關研究被迫中止。然而，對疫苗和治療方法的迫切需求推動了研發進程，使其以前所未有的速度發展，並展現了諸如主方案、適應性設計和分散式設計等方法的有效性。監管機構發布了大量指導意見，支援遠端監測和虛擬訪視，這些變革在後疫情時代基本上得以延續。儘管一些腫瘤和慢性病臨床試驗經歷了較長時間的延誤，但這場危機催生了一種更靈活、以患者為中心的模式，永久地改變了臨床實踐，並帶來了可衡量的效率提升。

在預測期內，第三階段預計將佔總量的最大部分。

預計在預測期內，III期臨床試驗將佔據最大的市場佔有率，這主要得益於監管部門核准所需的大規模、高投入的療效驗證試驗。這些大規模隨機對照試驗通常會在多個地區招募數百甚至數千名患者，並需要大量資源用於資料管理、監測和統計分析。第三期臨床試驗是上市核准前的最後一個也是最昂貴的步驟，通常會消耗藥物臨床開發總預算的50%至60%。由於申請需要較高的成功率，且罕見疾病產品線的擴展需要全球範圍內的III期臨床試驗項目，預計在整個預測期內，III期臨床試驗將保持市場主導地位。

在預測期內，「擴大准入測試」細分市場預計將呈現最高的複合年成長率。

在預測期內，「擴大用藥試驗」細分市場預計將呈現最高的成長率，這反映出監管機構日益重視向無法參與常規臨床試驗的嚴重患者提供臨床實驗藥物。這些項目，也稱為“同情用藥”或“特定患者用藥”，允許製藥公司在正式試驗方案之外提供核准的療法，同時收集安全性和治療結果數據。患者權益倡導活動的擴展、對治療方法可及性的認知提高以及監管流程的簡化，正在加速罕見疾病和腫瘤領域此類計畫的推廣應用。製藥公司越來越將擴大用藥視為道德義務，同時也是收集真實世界數據（REW）以支持更廣泛適應症的機會，這推動了該細分市場的持續成長。

市佔率最大的地區：

在預測期內，北美預計將佔據最大的市場佔有率，這得益於其成熟的臨床研究基礎設施、高額的醫療保健支出以及眾多大型製藥和生物技術公司的存在。該地區擁有龐大且多元化的患者群體、經驗豐富的臨床研究人員以及提供全面研發服務的成熟合約研究組織 (CRO)。美國食品藥物管理局 (FDA) 的快速核准系統提高了監管效率，鼓勵申辦者在美國啟動相當一部分全球臨床試驗。美國國立衛生研究院 (NIH) 對臨床研究的大量政府資助進一步加強了研究生態系統。這些結構性優勢確保北美在整個預測期內保持領先地位。

複合年成長率最高的地區：

在預測期內，亞太地區預計將呈現最高的複合年成長率，這主要得益於不斷擴大的患者群體、更低的營運成本以及新興經濟體監管基礎設施的完善。中國、印度和韓國等國家正大力推動臨床試驗法規的現代化，縮短核准時間，同時加強倫理監管。大量初治患者的存在，使得全球製藥公司和正在拓展研發能力的本土生技公司能夠快速招募受試者。與西方市場相比，亞太地區在臨床實驗管理、實驗室服務和資料管理方面的成本優勢，為臨床實驗轉移提供了強大的經濟獎勵。隨著亞太地區不斷建立世界臨床實驗的研究中心和臨床實驗網路，該地區的臨床開發投資也持續成長。

免費客製化服務：

所有購買此報告的客戶均可享受以下免費自訂選項之一：

  • 企業概況
    • 對其他市場參與者（最多 3 家公司）進行全面分析
    • 對主要公司進行SWOT分析（最多3家公司）
  • 區域細分
    • 應客戶要求，我們提供主要國家的市場估算和預測，以及複合年成長率（註：需進行可行性檢查）。
  • 競爭性標竿分析
    • 根據產品系列、地理覆蓋範圍和策略聯盟對領先公司進行基準分析。

目錄

第1章執行摘要

  • 市場概覽及主要亮點
  • 促進因素、挑戰與機遇
  • 競爭格局概述
  • 戰略洞察與建議

第2章：研究框架

  • 研究目標和範圍
  • 相關人員分析
  • 研究假設和限制
  • 調查方法

第3章 市場動態與趨勢分析

  • 市場定義與結構
  • 主要市場促進因素
  • 市場限制與挑戰
  • 投資成長機會和重點領域
  • 產業威脅與風險評估
  • 技術與創新展望
  • 新興市場/高成長市場
  • 監管和政策環境
  • 新冠疫情的影響及復甦前景

第4章：競爭環境與策略評估

  • 波特五力分析
    • 供應商的議價能力
    • 買方的議價能力
    • 替代品的威脅
    • 新進入者的威脅
    • 競爭公司之間的競爭
  • 主要公司市佔率分析
  • 產品基準評效和效能比較

第5章 全球臨床試驗市場：依階段分類

  • 第一階段
  • 第二階段
  • 第三階段
  • 第四階段

第6章 全球臨床試驗市場：依研究設計分類

  • 干預試驗
  • 觀察性研究
  • 擴展准入測試

第7章 全球臨床試驗市場：依適應症（治療領域）分類

  • 腫瘤學
  • 心血管疾病
  • 神經病學
  • 感染疾病
  • 代謝性疾病
  • 呼吸系統疾病
  • 消化系統疾病
  • 皮膚科
  • 眼科
  • 泌尿生殖/女性醫學
  • 罕見疾病
  • 其他改編

第8章 全球臨床試驗市場：依干預類型分類

  • 藥物測試
  • 生物製藥的臨床試驗
  • 醫療設備測試
  • 細胞和基因治療試驗
  • 疫苗試驗

第9章 全球臨床試驗市場：依最終使用者分類

  • 製藥公司
  • 生技公司
  • 醫療設備製造商
  • 學術研究機構
  • 政府機構

第10章 全球臨床試驗市場：按地區分類

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 荷蘭
    • 比利時
    • 瑞典
    • 瑞士
    • 波蘭
    • 其他歐洲國家
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 泰國
    • 馬來西亞
    • 新加坡
    • 越南
    • 其他亞太國家
  • 南美洲
    • 巴西
    • 阿根廷
    • 哥倫比亞
    • 智利
    • 秘魯
    • 其他南美國家
  • 世界其他地區（RoW）
    • 中東
      • 沙烏地阿拉伯
      • 阿拉伯聯合大公國
      • 卡達
      • 以色列
      • 其他中東國家
    • 非洲
      • 南非
      • 埃及
      • 摩洛哥
      • 其他非洲國家

第11章 策略市場資訊

  • 工業價值網路和供應鏈評估
  • 空白區域和機會地圖
  • 產品演進與市場生命週期分析
  • 通路、經銷商和打入市場策略的評估

第12章 產業趨勢與策略舉措

  • 併購
  • 夥伴關係、聯盟和合資企業
  • 新產品發布和認證
  • 擴大生產能力和投資
  • 其他策略舉措

第13章：公司簡介

  • IQVIA Holdings Inc
  • Labcorp Holdings Inc
  • Parexel International Corporation
  • Syneos Health Inc
  • ICON plc
  • Charles River Laboratories International Inc
  • PPD Inc
  • Medpace Holdings Inc
  • WuXi AppTec Co Ltd
  • Thermo Fisher Scientific Inc
  • Covance Inc
  • Clinipace Inc
  • KCR SA
  • Pharmaron Beijing Co Ltd
  • SGS SA
Product Code: SMRC35982

According to Stratistics MRC, the Global Clinical Trials Market is accounted for $87.3 billion in 2026 and is expected to reach $160.4 billion by 2034 growing at a CAGR of 7.9% during the forecast period. Clinical trials are research studies conducted on human participants to evaluate the safety, efficacy, and side effects of medical interventions including drugs, biologics, devices, and treatment protocols. These studies form the backbone of evidence-based medicine, providing the critical data required for regulatory approval by authorities such as the FDA and EMA. The market encompasses a complex ecosystem of pharmaceutical sponsors, contract research organizations (CROs), clinical sites, and technology providers working together to advance therapeutic development across diverse disease areas.

Market Dynamics:

Driver:

Rising prevalence of chronic and rare diseases

The global burden of chronic conditions including cancer, diabetes, and cardiovascular disorders continues to escalate, creating urgent demand for novel therapeutic interventions. Simultaneously, increased understanding of genetic mechanisms has enabled targeted drug development for thousands of rare diseases that previously lacked treatment options. This dual pressure on healthcare systems drives pharmaceutical companies to expand their clinical development pipelines across multiple therapeutic areas. Government incentives for orphan drug development and accelerated regulatory pathways further encourage investment in clinical research, with the number of registered trials growing annually as sponsors race to bring innovative therapies to patients with limited existing treatment alternatives.

Restraint:

High patient recruitment and retention challenges

Successful clinical trial execution depends on enrolling eligible participants within timelines, yet recruitment difficulties remain the single greatest cause of study delays and terminations. Identifying appropriate candidates who meet complex inclusion and exclusion criteria requires extensive site networks and patient outreach efforts. Once enrolled, maintaining participant compliance with protocol requirements, scheduled visits, and often burdensome procedures presents ongoing challenges that can compromise data quality. These recruitment and retention issues extend development timelines, increase costs, and may produce underpowered results requiring additional confirmatory studies, creating substantial financial pressure on sponsors and particularly affecting trials for rare diseases with limited patient populations.

Opportunity:

Decentralized and virtual trial methodologies

The adoption of digital health technologies is fundamentally transforming how clinical research is conducted by enabling remote participation and data collection. Wearable sensors, mobile applications, and telemedicine platforms allow patients to contribute data from home, reducing geographic barriers and travel burdens that limit traditional site-based enrollment. Electronic informed consent, direct-to-patient drug shipment, and home health visits further expand access to diverse populations, improving trial generalizability. These decentralized approaches have demonstrated accelerated recruitment timelines and reduced dropout rates while capturing richer real-world data, creating significant opportunities for sponsors to improve development efficiency and reduce the expanding costs of clinical research.

Threat:

Changing regulatory and compliance landscapes

Evolving and increasingly complex global regulatory requirements pose significant threats to predictable clinical development timelines and budgets. Divergent requirements across major markets for data standards, safety reporting, and ethical oversight create substantial operational burdens for sponsors conducting multinational trials. Emerging regulations around data privacy, including GDPR and comparable frameworks, restrict the collection and cross-border transfer of participant information essential for modern research. Additionally, heightened scrutiny of diversity and representation in clinical trials requires sponsors to redesign recruitment strategies and expand site footprints. Navigating this dynamic compliance environment demands continuous investment in expertise and systems, eroding profit margins for contract research organizations.

Covid-19 Impact:

The COVID-19 pandemic created unprecedented disruption for clinical trials while simultaneously accelerating adoption of innovative research methodologies. During early 2020, thousands of non-COVID studies were paused as sites halted enrollment and redirected resources toward pandemic response. However, the urgent need for vaccines and therapeutics drove record-fast development timelines, validating approaches including master protocols, adaptive designs, and decentralized elements. Regulators issued extensive guidance enabling remote monitoring and virtual visits, changes that have largely persisted post-pandemic. While some oncology and chronic disease trials experienced lasting delays, the crisis permanently reshaped clinical operations toward more flexible, patient-centric models delivering measurable efficiency improvements.

The Phase III segment is expected to be the largest during the forecast period

The Phase III segment is expected to account for the largest market share during the forecast period, driven by the substantial scale and investment associated with confirmatory efficacy studies required for regulatory approval. These large, randomized controlled trials typically enroll hundreds or thousands of patients across multiple geographic regions and require significant resources for data management, monitoring, and statistical analysis. Phase III studies represent the final and most expensive step before marketing authorization, often consuming 50-60% of a drug's total clinical development budget. The high success rates required for submission and the expansion of rare disease pipelines requiring global Phase III programs ensure this phase maintains dominant market position throughout the forecast timeline.

The Expanded Access Trials segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the Expanded Access Trials segment is predicted to witness the highest growth rate, reflecting increased regulatory emphasis on providing investigational therapies to seriously ill patients who cannot enroll in traditional clinical trials. These programs, also known as compassionate use or named patient access, allow manufacturers to provide unapproved treatments outside of formal study protocols while collecting safety and outcomes data. Growing patient advocacy, heightened awareness of treatment availability, and streamlined regulatory pathways are accelerating program adoption across rare diseases and oncology. Pharmaceutical companies increasingly view expanded access as both an ethical obligation and an opportunity to gather real-world evidence supporting broader indications, driving sustained segment expansion.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share, supported by a mature clinical research infrastructure, high healthcare expenditure, and the presence of major pharmaceutical and biotechnology sponsors. The region benefits from large and diverse patient populations, experienced clinical investigators, and established contract research organizations offering comprehensive development services. Regulatory efficiency through the FDA's expedited pathways encourages sponsors to initiate a substantial proportion of global trials within the United States. Significant government funding for clinical research through the National Institutes of Health further strengthens the research ecosystem. These structural advantages ensure North America maintains leadership throughout the forecast period.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR, driven by expanding patient populations, lower operational costs, and improving regulatory infrastructure across emerging economies. Countries including China, India, and South Korea have substantially modernized their clinical trial regulations, reducing approval timelines while enhancing ethical oversight. Large treatment-naive patient populations enable rapid recruitment for both global pharmaceutical sponsors and domestic biotech companies expanding their research capabilities. Cost advantages for site management, laboratory services, and data management compared to Western markets create compelling economic incentives for trial migration. As Asia Pacific continues developing world-class research sites and investigator networks, the region captures increasing clinical development investment.

Key players in the market

Some of the key players in Clinical Trials Market include IQVIA Holdings Inc, Labcorp Holdings Inc, Parexel International Corporation, Syneos Health Inc, ICON plc, Charles River Laboratories International Inc, PPD Inc, Medpace Holdings Inc, WuXi AppTec Co Ltd, Thermo Fisher Scientific Inc, Covance Inc, Clinipace Inc, KCR SA, Pharmaron Beijing Co Ltd, and SGS SA.

Key Developments:

In January 2026, Thermo Fisher launched the CorEvitas Obesity Registry, expanding its real-world evidence (RWE) capabilities to address the surging demand for clinical data in the cardiometabolic sector.

In September 2025, WuXi AppTec Co Ltd completed the expansion of Taixing peptide capacity ahead of schedule, bringing total reactor volume to over 100,000L to meet the global demand for TIDES (oligo and peptide) therapeutics.

In September 2025, Parexel entered an AI partnership with Weave Bio to integrate an AI-native platform into regulatory submission processes, aiming to accelerate the market introduction of new therapies.

Phases Covered:

  • Phase I
  • Phase II
  • Phase III
  • Phase IV

Study Designs Covered:

  • Interventional Studies
  • Observational Studies
  • Expanded Access Trials

Indications (Therapeutic Area) Covered:

  • Oncology
  • Cardiovascular Diseases
  • Neurology
  • Infectious Diseases
  • Metabolic Disorders
  • Respiratory Diseases
  • Gastrointestinal Diseases
  • Dermatology
  • Ophthalmology
  • Genitourinary & Women's Health
  • Rare Diseases
  • Other Indications

Intervention Types Covered:

  • Drug Trials
  • Biologics Trials
  • Medical Device Trials
  • Cell & Gene Therapy Trials
  • Vaccine Trials

End Users Covered:

  • Pharmaceutical Companies
  • Biotechnology Companies
  • Medical Device Companies
  • Academic & Research Institutes
  • Government Organizations

Regions Covered:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • United Kingdom
    • Germany
    • France
    • Italy
    • Spain
    • Netherlands
    • Belgium
    • Sweden
    • Switzerland
    • Poland
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Thailand
    • Malaysia
    • Singapore
    • Vietnam
    • Rest of Asia Pacific
  • South America
    • Brazil
    • Argentina
    • Colombia
    • Chile
    • Peru
    • Rest of South America
  • Rest of the World (RoW)
    • Middle East
  • Saudi Arabia
  • United Arab Emirates
  • Qatar
  • Israel
  • Rest of Middle East
    • Africa
  • South Africa
  • Egypt
  • Morocco
  • Rest of Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

  • 1.1 Market Snapshot and Key Highlights
  • 1.2 Growth Drivers, Challenges, and Opportunities
  • 1.3 Competitive Landscape Overview
  • 1.4 Strategic Insights and Recommendations

2 Research Framework

  • 2.1 Study Objectives and Scope
  • 2.2 Stakeholder Analysis
  • 2.3 Research Assumptions and Limitations
  • 2.4 Research Methodology
    • 2.4.1 Data Collection (Primary and Secondary)
    • 2.4.2 Data Modeling and Estimation Techniques
    • 2.4.3 Data Validation and Triangulation
    • 2.4.4 Analytical and Forecasting Approach

3 Market Dynamics and Trend Analysis

  • 3.1 Market Definition and Structure
  • 3.2 Key Market Drivers
  • 3.3 Market Restraints and Challenges
  • 3.4 Growth Opportunities and Investment Hotspots
  • 3.5 Industry Threats and Risk Assessment
  • 3.6 Technology and Innovation Landscape
  • 3.7 Emerging and High-Growth Markets
  • 3.8 Regulatory and Policy Environment
  • 3.9 Impact of COVID-19 and Recovery Outlook

4 Competitive and Strategic Assessment

  • 4.1 Porter's Five Forces Analysis
    • 4.1.1 Supplier Bargaining Power
    • 4.1.2 Buyer Bargaining Power
    • 4.1.3 Threat of Substitutes
    • 4.1.4 Threat of New Entrants
    • 4.1.5 Competitive Rivalry
  • 4.2 Market Share Analysis of Key Players
  • 4.3 Product Benchmarking and Performance Comparison

5 Global Clinical Trials Market, By Phase

  • 5.1 Phase I
  • 5.2 Phase II
  • 5.3 Phase III
  • 5.4 Phase IV

6 Global Clinical Trials Market, By Study Design

  • 6.1 Interventional Studies
  • 6.2 Observational Studies
  • 6.3 Expanded Access Trials

7 Global Clinical Trials Market, By Indication (Therapeutic Area)

  • 7.1 Oncology
  • 7.2 Cardiovascular Diseases
  • 7.3 Neurology
  • 7.4 Infectious Diseases
  • 7.5 Metabolic Disorders
  • 7.6 Respiratory Diseases
  • 7.7 Gastrointestinal Diseases
  • 7.8 Dermatology
  • 7.9 Ophthalmology
  • 7.10 Genitourinary & Women's Health
  • 7.11 Rare Diseases
  • 7.12 Other Indications

8 Global Clinical Trials Market, By Intervention Type

  • 8.1 Drug Trials
  • 8.2 Biologics Trials
  • 8.3 Medical Device Trials
  • 8.4 Cell & Gene Therapy Trials
  • 8.5 Vaccine Trials

9 Global Clinical Trials Market, By End User

  • 9.1 Pharmaceutical Companies
  • 9.2 Biotechnology Companies
  • 9.3 Medical Device Companies
  • 9.4 Academic & Research Institutes
  • 9.5 Government Organizations

10 Global Clinical Trials Market, By Geography

  • 10.1 North America
    • 10.1.1 United States
    • 10.1.2 Canada
    • 10.1.3 Mexico
  • 10.2 Europe
    • 10.2.1 United Kingdom
    • 10.2.2 Germany
    • 10.2.3 France
    • 10.2.4 Italy
    • 10.2.5 Spain
    • 10.2.6 Netherlands
    • 10.2.7 Belgium
    • 10.2.8 Sweden
    • 10.2.9 Switzerland
    • 10.2.10 Poland
    • 10.2.11 Rest of Europe
  • 10.3 Asia Pacific
    • 10.3.1 China
    • 10.3.2 Japan
    • 10.3.3 India
    • 10.3.4 South Korea
    • 10.3.5 Australia
    • 10.3.6 Indonesia
    • 10.3.7 Thailand
    • 10.3.8 Malaysia
    • 10.3.9 Singapore
    • 10.3.10 Vietnam
    • 10.3.11 Rest of Asia Pacific
  • 10.4 South America
    • 10.4.1 Brazil
    • 10.4.2 Argentina
    • 10.4.3 Colombia
    • 10.4.4 Chile
    • 10.4.5 Peru
    • 10.4.6 Rest of South America
  • 10.5 Rest of the World (RoW)
    • 10.5.1 Middle East
      • 10.5.1.1 Saudi Arabia
      • 10.5.1.2 United Arab Emirates
      • 10.5.1.3 Qatar
      • 10.5.1.4 Israel
      • 10.5.1.5 Rest of Middle East
    • 10.5.2 Africa
      • 10.5.2.1 South Africa
      • 10.5.2.2 Egypt
      • 10.5.2.3 Morocco
      • 10.5.2.4 Rest of Africa

11 Strategic Market Intelligence

  • 11.1 Industry Value Network and Supply Chain Assessment
  • 11.2 White-Space and Opportunity Mapping
  • 11.3 Product Evolution and Market Life Cycle Analysis
  • 11.4 Channel, Distributor, and Go-to-Market Assessment

12 Industry Developments and Strategic Initiatives

  • 12.1 Mergers and Acquisitions
  • 12.2 Partnerships, Alliances, and Joint Ventures
  • 12.3 New Product Launches and Certifications
  • 12.4 Capacity Expansion and Investments
  • 12.5 Other Strategic Initiatives

13 Company Profiles

  • 13.1 IQVIA Holdings Inc
  • 13.2 Labcorp Holdings Inc
  • 13.3 Parexel International Corporation
  • 13.4 Syneos Health Inc
  • 13.5 ICON plc
  • 13.6 Charles River Laboratories International Inc
  • 13.7 PPD Inc
  • 13.8 Medpace Holdings Inc
  • 13.9 WuXi AppTec Co Ltd
  • 13.10 Thermo Fisher Scientific Inc
  • 13.11 Covance Inc
  • 13.12 Clinipace Inc
  • 13.13 KCR SA
  • 13.14 Pharmaron Beijing Co Ltd
  • 13.15 SGS SA

List of Tables

  • Table 1 Global Clinical Trials Market Outlook, By Region (2023-2034) ($MN)
  • Table 2 Global Clinical Trials Market Outlook, By Phase (2023-2034) ($MN)
  • Table 3 Global Clinical Trials Market Outlook, By Phase I (2023-2034) ($MN)
  • Table 4 Global Clinical Trials Market Outlook, By Phase II (2023-2034) ($MN)
  • Table 5 Global Clinical Trials Market Outlook, By Phase III (2023-2034) ($MN)
  • Table 6 Global Clinical Trials Market Outlook, By Phase IV (2023-2034) ($MN)
  • Table 7 Global Clinical Trials Market Outlook, By Study Design (2023-2034) ($MN)
  • Table 8 Global Clinical Trials Market Outlook, By Interventional Studies (2023-2034) ($MN)
  • Table 9 Global Clinical Trials Market Outlook, By Observational Studies (2023-2034) ($MN)
  • Table 10 Global Clinical Trials Market Outlook, By Expanded Access Trials (2023-2034) ($MN)
  • Table 11 Global Clinical Trials Market Outlook, By Indication (Therapeutic Area) (2023-2034) ($MN)
  • Table 12 Global Clinical Trials Market Outlook, By Oncology (2023-2034) ($MN)
  • Table 13 Global Clinical Trials Market Outlook, By Cardiovascular Diseases (2023-2034) ($MN)
  • Table 14 Global Clinical Trials Market Outlook, By Neurology (2023-2034) ($MN)
  • Table 15 Global Clinical Trials Market Outlook, By Infectious Diseases (2023-2034) ($MN)
  • Table 16 Global Clinical Trials Market Outlook, By Metabolic Disorders (2023-2034) ($MN)
  • Table 17 Global Clinical Trials Market Outlook, By Respiratory Diseases (2023-2034) ($MN)
  • Table 18 Global Clinical Trials Market Outlook, By Gastrointestinal Diseases (2023-2034) ($MN)
  • Table 19 Global Clinical Trials Market Outlook, By Dermatology (2023-2034) ($MN)
  • Table 20 Global Clinical Trials Market Outlook, By Ophthalmology (2023-2034) ($MN)
  • Table 21 Global Clinical Trials Market Outlook, By Genitourinary & Women's Health (2023-2034) ($MN)
  • Table 22 Global Clinical Trials Market Outlook, By Rare Diseases (2023-2034) ($MN)
  • Table 23 Global Clinical Trials Market Outlook, By Other Indications (2023-2034) ($MN)
  • Table 24 Global Clinical Trials Market Outlook, By Intervention Type (2023-2034) ($MN)
  • Table 25 Global Clinical Trials Market Outlook, By Drug Trials (2023-2034) ($MN)
  • Table 26 Global Clinical Trials Market Outlook, By Biologics Trials (2023-2034) ($MN)
  • Table 27 Global Clinical Trials Market Outlook, By Medical Device Trials (2023-2034) ($MN)
  • Table 28 Global Clinical Trials Market Outlook, By Cell & Gene Therapy Trials (2023-2034) ($MN)
  • Table 29 Global Clinical Trials Market Outlook, By Vaccine Trials (2023-2034) ($MN)
  • Table 30 Global Clinical Trials Market Outlook, By End User (2023-2034) ($MN)
  • Table 31 Global Clinical Trials Market Outlook, By Pharmaceutical Companies (2023-2034) ($MN)
  • Table 32 Global Clinical Trials Market Outlook, By Biotechnology Companies (2023-2034) ($MN)
  • Table 33 Global Clinical Trials Market Outlook, By Medical Device Companies (2023-2034) ($MN)
  • Table 34 Global Clinical Trials Market Outlook, By Academic & Research Institutes (2023-2034) ($MN)
  • Table 35 Global Clinical Trials Market Outlook, By Government Organizations (2023-2034) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Rest of the World (RoW) Regions are also represented in the same manner as above.